Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation

Summary

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK of HSK42360 when given orally in pediatric patients with active BRAF V600 mutation recurrent malignant brain tumors.

Timeline

Start

2025-08-15

Primary completion

2029-05-23

Completion

2029-12-03

Drugs

Indications